Literature DB >> 27349451

Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy.

Kangdi Zheng, Qiong Wu, Chengxi Wang, Weijun Tan1, Wenjie Mei2.   

Abstract

Herein, the development of ruthenium complexes as potential apoptosis inducers, as well as their underlying mechanism has been reviewed. In recent years, various ruthenium complexes have been designed and their in vitro and in vivo inhibitory activities against various types of tumor cells have been evaluated extensively. It's demonstrated that ruthenium complexes can induce apoptosis of tumor cells through the signal pathway of mitochondria-mediated, death receptor-mediated, and/or endoplasmic reticulum (ER) stress pathways. Alternately, the binding behavior of these ruthenium(II) complexes with DNA, especially with Gquadruplex DNA may play a key role in the DNA damage of tumor cells, and thus provides a versatile tool to rational design novel ruthenium complexes with high activity and selectivity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27349451

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  7 in total

Review 1.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

2.  Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells.

Authors:  Cinara O D'Sousa Costa; João H Araujo Neto; Ingrid R S Baliza; Rosane B Dias; Ludmila de F Valverde; Manuela T A Vidal; Caroline B S Sales; Clarissa A G Rocha; Diogo R M Moreira; Milena B P Soares; Alzir A Batista; Daniel P Bezerra
Journal:  Oncotarget       Date:  2017-11-01

3.  Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.

Authors:  Carlo Irace; Gabriella Misso; Antonella Capuozzo; Marialuisa Piccolo; Claudia Riccardi; Alessandra Luchini; Michele Caraglia; Luigi Paduano; Daniela Montesarchio; Rita Santamaria
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

4.  New Heteroleptic Ruthenium(II) Complexes with Sulfamethoxypyridazine and Diimines as Potential Antitumor Agents.

Authors:  Ariane C C de Melo; Jaime M S V P Santana; Kelen J R C Nunes; Bernardo L Rodrigues; Nathalia Castilho; Philipe Gabriel; Adolfo H Moraes; Mayra de A Marques; Guilherme A P de Oliveira; Ívina P de Souza; Hernán Terenzi; Elene C Pereira-Maia
Journal:  Molecules       Date:  2019-06-07       Impact factor: 4.411

Review 5.  Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.

Authors:  Claudia Riccardi; Domenica Musumeci; Marco Trifuoggi; Carlo Irace; Luigi Paduano; Daniela Montesarchio
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-26

Review 6.  Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Francesco Maione; Daniela Montesarchio; Michele Caraglia; Luigi Paduano; Rita Santamaria; Carlo Irace
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

7.  Induction of Redox-Mediated Cell Death in ER-Positive and ER-Negative Breast Cancer Cells by a Copper(II)-Phenolate Complex: An In Vitro and In Silico Study.

Authors:  Vaiyapuri Subbarayan Periasamy; Anvarbatcha Riyasdeen; Venugopal Rajendiran; Mallayan Palaniandavar; Hanumanthappa Krishnamurthy; Ali Abdullah Alshatwi; Mohammad Abdulkader Akbarsha
Journal:  Molecules       Date:  2020-10-01       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.